Dr Reddys Laboratories (RDY) Receivables - Net (2009 - 2026)

Dr Reddys Laboratories has reported Receivables - Net for 18 years, with the latest figure at $1.1 billion in Q2 2026.

• On a quarterly basis, Receivables - Net fell 4.45% year-over-year to $1.1 billion in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 4.45% decrease from a year earlier, with the FY2026 full-year figure at $1.1 billion, up 1.98% from the prior year.
• Receivables - Net was $1.1 billion for Q2 2026 at Dr Reddys Laboratories, down from $1.1 billion in the prior quarter.
• The five-year high for Receivables - Net was $1.2 billion in Q4 2025, with the low at $843.4 million in Q3 2023.
• Average Receivables - Net over 5 years is $998.2 million, with a median of $969.5 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net jumped 3013.51% in 2022, then fell 12.66% in 2023.
• Over 5 years, Receivables - Net stood at $914.1 million in 2022, then rose by 3.03% to $941.8 million in 2023, then grew by 15.96% to $1.1 billion in 2024, then increased by 6.12% to $1.2 billion in 2025, then dropped by 8.35% to $1.1 billion in 2026.
• The last three Receivables - Net figures came in at $1.1 billion (Q2 2026), $1.1 billion (Q1 2026), and $1.2 billion (Q4 2025), per Business Quant data.